PSA Doubling Time Calculator

Understanding PSA Doubling Time

This PSA doubling time calculator estimates how quickly PSA is rising — a key metric for monitoring prostate cancer. Prostate-specific antigen (PSA) is a protein produced by prostate gland cells, and blood levels are used to screen for and monitor prostate cancer. A single PSA value is difficult to interpret in isolation — the trend over time (PSA kinetics) provides far more clinical information. PSA doubling time (PSADT) estimates how long it would take for PSA to double, assuming exponential growth. It is expressed in months.

PSADT is used in several clinical contexts: active surveillance of low-risk prostate cancer, monitoring after treatment (radical prostatectomy or radiation therapy), and assessing response to androgen deprivation therapy. A fast PSADT signals aggressive disease; a slow PSADT suggests indolent behavior. For other biomarker doubling-time calculations, the HCG doubling time calculator follows the same exponential-growth methodology applied to hCG levels.

How PSADT Is Calculated

For two measurements, the formula is:

PSADT (months) = Time Between Tests (months) × ln(2) ÷ ln(PSA₂ ÷ PSA₁)

When three or more measurements are available, least-squares linear regression on log-transformed PSA values provides a more accurate estimate that is less sensitive to the noise of any single measurement. This calculator automatically switches to regression when 3+ valid readings are entered.

Clinical Interpretation by PSADT

• PSADT >10 years (120+ months): Low concern — consistent with indolent disease or benign growth. Active surveillance may continue without intensification.
• PSADT 3–10 years (36–120 months): Moderate concern — increased surveillance frequency recommended. Discuss with urologist whether imaging or biopsy is warranted.
• PSADT <3 years (36 months): High concern — associated with higher risk of metastasis and cancer-specific mortality. Prompt urologic evaluation and likely treatment discussion needed.
• PSA Velocity >0.75 ng/mL/year: This threshold is associated with increased biopsy detection of prostate cancer and biochemical recurrence after therapy.

PSADT is most reliable when calculated from at least 3 measurements spanning 6–12 months, with PSA values that are consistently rising.

PSADT After Treatment (Biochemical Recurrence)

After radical prostatectomy, PSA should fall to undetectable levels (<0.1 ng/mL). Any rise above 0.2–0.4 ng/mL on two consecutive measurements is considered biochemical recurrence (BCR). After radiation, the PSA nadir +2 ng/mL criterion (Phoenix definition) defines BCR. In both settings, PSADT is a key predictor of distant metastasis — PSADT <15 months post-prostatectomy is strongly associated with metastatic progression, and PSADT <3 months confers very poor prognosis without salvage therapy.

Normal PSA Levels by Age

PSA levels rise naturally with age due to prostate growth, inflammation, and the increased likelihood of early prostate cancer. Age-adjusted PSA reference ranges (ng/mL):

• Age 40–49: Normal < 2.5 ng/mL
• Age 50–59: Normal < 3.5 ng/mL
• Age 60–69: Normal < 4.5 ng/mL
• Age 70–79: Normal < 6.5 ng/mL

The traditional threshold of 4.0 ng/mL applies broadly but may miss cancer in younger men (who have lower natural PSA) and lead to unnecessary biopsies in older men. The American Urological Association now emphasizes shared decision-making that considers absolute PSA value, rate of change (velocity and doubling time), patient age and life expectancy, and comorbidities.

A PSA that falls within age-normal range but is rising rapidly (PSADT < 3 years or velocity > 0.75 ng/mL/year) may warrant further evaluation even without crossing the absolute threshold. Conversely, an elevated but stable PSA over many years is less concerning than one that is rising quickly.

PSA Velocity vs. PSA Doubling Time — Which Is More Useful?

PSA velocity (PSAV) and PSA doubling time (PSADT) both capture how rapidly PSA is changing, but they have different mathematical properties and clinical applications:

• PSA Velocity — measured in ng/mL/year; the linear rate of increase. Easier to communicate to patients and more intuitive. A velocity of > 0.75 ng/mL/year has historically been associated with cancer detection and recurrence. PSAV is most useful when PSA levels are relatively low (< 10 ng/mL).
• PSA Doubling Time — expressed in months; the exponential growth rate. More statistically robust because cancer growth is typically exponential rather than linear. More useful at higher PSA levels and for monitoring after treatment. PSADT < 15 months after radical prostatectomy is strongly associated with metastatic progression and cancer-specific mortality.
• Which to use — PSADT is generally preferred in oncology research and for post-treatment monitoring. PSAV can be used for initial screening context. Both are complementary and this calculator provides both simultaneously.

For patients on active surveillance for low-risk prostate cancer, both metrics should be tracked over time. Any PSADT < 3 years during active surveillance typically prompts discussion of transitioning to active treatment. See the GFR calculator for kidney function monitoring that may affect treatment options.

Limitations of PSADT Calculation

PSADT assumes continuous exponential growth, which may not hold over long time periods or across treatment changes. Measurements from different laboratory methods or assays can introduce systematic differences. PSA can temporarily spike after prostate biopsy, catheterization, or acute prostatitis — including such values in the calculation will produce misleading results. Always use measurements from the same lab, obtained at least 6–8 weeks after any procedure, for the most accurate PSADT estimate.

For complementary kidney function monitoring that may affect some prostate cancer treatments, see the GFR calculator.